Small Lymphocytic Lymphoma (SLL) | Tumor

FDA Approves Calquence for Leukemia and Lymphoma Subsets

November 21st 2019, 10:18pm

Article

In partnership with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the Food and Drug Administration (FDA) has granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

FDA Approves Venclexta-Gazyva Combo as Frontline Treatment for CLL/SLL

May 15th 2019, 11:43pm

Article

The Food and Drug Administration has approved the combination use of Venclexta plus Gazyva for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

2018 FDA Advancements in Small Lymphocytic Leukemia

November 29th 2018, 7:59pm

Article

Take a look at the FDA’s decisions for the treatment of SLL that happened this year.

Imbruvica Yields Favorable Safety Outcomes in Two Types of Lymphomas

November 12th 2018, 11:17pm

Article

Imbruvica (ibrutinib) is a safe treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), according to a pooled analysis of four clinical trials.

FDA Approves Copiktra for Two Types of Blood Cancer

September 25th 2018, 12:00am

Article

The drug was approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. And was granted an accelerated approval for follicular lymphoma.